Gain Therapeutics Inc. (NASDAQ: GANX) presented interim results from its Phase 1b clinical study of GT-02287 in Parkinson's disease patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE